AltMountain

Gordonmd Global Investments LP

Beverly Hills, CA · CRD 316751
Hedge fund manager

Gordonmd Global Investments LP is an SEC-registered investment adviser based in Beverly Hills, CA that reports managing 1 hedge fund on Form ADV. It reports $322.3 million in regulatory assets under management. Its private funds, of all types, hold $322.3 million in gross assets. Its disclosed U.S. stock holdings returned an estimated +14.1% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +14.1% from Q1 2026 to Q2 2026, compared with +9.5% for the S&P 500, based on 13F filings.

Regulatory assets under management
$322.3 millionForm ADV Item 5.F
Gross assets of private funds
$322.3 millionAll private fund types, Form ADV
Hedge funds managed
14 private funds in total
Employees
7Form ADV Item 5.A
Registration
SEC-registered adviserCRD 316751
Latest Form ADV
03/26/2026Disciplinary disclosures: none reported

Estimated 13F portfolio performance

Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.

Estimated from 13F · 2026 YTD+14.1%Through Q2 2026 · S&P 500 +9.5%
Estimated from 13F · 2 quarters+14.1%Q1 2026 – Q2 2026
S&P 500+9.5%Same quarters, price only
13F holdings$206.7 million16 positions, 2026-06-30
$95$105$114Q1 2026Q2 202613F est. $114S&P 500 $110
QuarterEst. 13F returnS&P 500
Q2 2026+18.6%+14.8%
Q1 2026-3.8%-4.6%

Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures

Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.

13F holdings as of Sep 30, 2026

All 14 share positions ($166,469,374) reported by GordonMD Global Investments LP on Form 13F for the quarter ended Sep 30, 2026, filed Nov 16, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.

Share of the reported 13F portfolio, ten largest positions

  • Pyxis Oncology Inc21.75%
  • Kyverna Therapeutics Inc18.47%
  • Teva Pharmaceutical Inds LTD9.03%
  • Celldex Therapeutics Inc New5.45%
  • Tango Therapeutics Inc5.42%
  • Vir Biotechnology Inc5.40%
  • Adarx Pharmaceuticals Inc5.39%
  • Allogene Therapeutics Inc5.09%
  • Bausch Plus Lomb Corp4.86%
  • Editas Medicine Inc4.83%
StockValue% of 13F portfolioSharesShares vs prior quarter
Pyxis Oncology Inc$36,212,64821.75%15,541,909+55.03%
Kyverna Therapeutics Inc$30,744,96218.47%4,521,318+6.51%
Teva Pharmaceutical Inds LTD$15,028,9929.03%379,520New
Celldex Therapeutics Inc New$9,065,7255.45%279,720Unchanged
Tango Therapeutics Inc$9,021,6515.42%1,852,495New
Vir Biotechnology Inc$8,983,7115.40%803,552-40.63%
Adarx Pharmaceuticals Inc$8,973,0005.39%450,000New
Allogene Therapeutics Inc$8,476,8005.09%5,298,000Unchanged
Bausch Plus Lomb Corp$8,083,0244.86%475,472-17.09%
Editas Medicine Inc$8,036,3904.83%3,127,000Unchanged
Incyte Corp$6,198,5583.72%51,080+17.97%
Taysha Gene Therapies Inc$6,187,6003.72%248,000-65.71%
Amgen Inc$6,116,9533.67%14,512-28.20%
Scholar Rock Hldg Corp$5,339,3603.21%110,500-16.60%

Changes since Jun 30, 2026

Comparing the share counts in the two quarter-end filings: 3 new positions, 5 sold out, 3 increased, 5 reduced and 3 unchanged.

Number of positions (a count, not dollars)

  • New positions3
  • Increased3
  • Unchanged3
  • Reduced5
  • Sold out5

New positions

StockValueShares
Teva Pharmaceutical Inds LTD$15,028,992379,520
Tango Therapeutics Inc$9,021,6511,852,495
Adarx Pharmaceuticals Inc$8,973,000450,000

Sold out

StockValue at Jun 30, 2026Shares held then
Teva Pharmaceutical Inds LTD$16,360,9912,402,495
Ultragenyx Pharmaceutical In$9,653,082289,101
Sionna Therapeutics Inc$5,982,640136,000
Crinetics Pharmaceuticals In$4,751,779126,985
Insmed Inc$3,047,94628,587

Largest increases

StockChange in sharesChangeValue nowShares now
Pyxis Oncology Inc+5,517,000+55.03%$36,212,64815,541,909
Kyverna Therapeutics Inc+276,500+6.51%$30,744,9624,521,318
Incyte Corp+7,780+17.97%$6,198,55851,080

Largest reductions

StockChange in sharesChangeValue nowShares now
Taysha Gene Therapies Inc-475,185-65.71%$6,187,600248,000
Vir Biotechnology Inc-550,000-40.63%$8,983,711803,552
Amgen Inc-5,700-28.20%$6,116,95314,512
Bausch Plus Lomb Corp-98,000-17.09%$8,083,024475,472
Scholar Rock Hldg Corp-22,000-16.60%$5,339,360110,500

Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.

From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures

Large ownership stakes (Schedule 13D and 13G)

CompanyFilingPercent of classSharesFiledSource
Kyverna Therapeutics, Inc.13G amendment7.34%4,521,318Nov 16, 2026SEC.gov ↗
Pyxis Oncology, Inc.13G amendment16.4%20,441,948Oct 9, 2026SEC.gov ↗

A firm files Schedule 13G (passive) or 13D (it may seek to influence the company) when it beneficially owns more than 5% of a class of a public company's shares. Each row is the firm's latest such filing for that company since Oct 9, 2026, exactly as filed, and counts shares held across the firm and its affiliates, not by any single fund. An amendment can report a stake that has fallen below 5%. Holdings may have changed since the filing date. Not verified by AltMountain. Source: U.S. Securities and Exchange Commission, EDGAR.

Hedge funds filing Form D (2)

Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.

Private equity funds filing Form D (2)

Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.

Private funds reported on Form ADV (2)

Fund
Gross assets
Minimum
Owners
Adviser
Gordonmd Long Biased Master Fund LP
Cayman IslandsHedge fund
Gross assets$97.8M
Minimum$250K
Owners24
AdviserGordonmd Global Investments LP
Gordonmd PE Fund LP
Delaware, United StatesPrivate equity fund
Gross assets$63.5M
Minimum$5.0M
Owners24
AdviserGordonmd Global Investments LP

As reported in the adviser's Form ADV filed Mar 20, 2024. Funds also listed from Form D are shown above.

From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures⁠​​‌‌‌‌‌‌‌​‌‌‌‌‌‌‌‌‌‌⁠